Literature DB >> 7824278

Phosphorylation of a specific cdk site in E2F-1 affects its electrophoretic mobility and promotes pRB-binding in vitro.

D S Peeper1, P Keblusek, K Helin, M Toebes, A J van der Eb, A Zantema.   

Abstract

The E2F transcription factor family participates in growth control presumably through transcriptional activation of genes that promote entry into S phase. E2F activity is believed to be controlled across the cell cycle by association with various cellular proteins, including the product of the retinoblastoma gene (pRB). We find that E2F-1 proteins are heterogeneously phosphorylated in insect cells, as a result of which they migrate as a doublet on SDS-polyacrylamide gels. This electrophoretic shift is shown to be dependent upon specific phosphorylation of E2F-1 on serine-375 (S375), near the pRB-binding site. Phosphorylation on S375 also occurs in human cells. E2F-1 was most efficiently phosphorylated on this residue by cyclin A/cdk2 kinase, and to a lesser extent by cyclin A/cdk2, irrespective of the presence of the pRB-related p107 protein. Phosphorylation of E2F-1 on S375 greatly enhanced its affinity of pRB in vitro. These results suggest a novel way of regulating E2F-1 activity, namely by cell-cycle-dependent phosphorylation of this transcription factor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7824278

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  p19ARF targets certain E2F species for degradation.

Authors:  F Martelli; T Hamilton; D P Silver; N E Sharpless; N Bardeesy; M Rokas; R A DePinho; D M Livingston; S R Grossman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Induction of S-phase entry by E2F transcription factors depends on their nuclear localization.

Authors:  H Müller; M C Moroni; E Vigo; B O Petersen; J Bartek; K Helin
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

3.  Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes.

Authors:  P D Adams; X Li; W R Sellers; K B Baker; X Leng; J W Harper; Y Taya; W G Kaelin
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

4.  E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry.

Authors:  K Moberg; M A Starz; J A Lees
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

5.  Identification of a viral kinase that phosphorylates specific E2Fs and pocket proteins.

Authors:  S Pajovic; E L Wong; A R Black; J C Azizkhan
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

6.  Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors.

Authors:  P D Adams; W R Sellers; S K Sharma; A D Wu; C M Nalin; W G Kaelin
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

7.  Induction of cyclins E and A in response to mitogen removal: a basic alteration associated with the arrest of differentiation of C2 myoblasts transformed by simian virus 40 large T antigen.

Authors:  D Tedesco; L Baron; L Fischer-Fantuzzi; C Vesco
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

8.  Molecular Determinants for the Inactivation of the Retinoblastoma Tumor Suppressor by the Viral Cyclin-dependent Kinase UL97.

Authors:  Satoko Iwahori; Morgan Hakki; Sunwen Chou; Robert F Kalejta
Journal:  J Biol Chem       Date:  2015-06-21       Impact factor: 5.157

9.  Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases.

Authors:  L M Schang; A Rosenberg; P A Schaffer
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

10.  E2F-1 binding affinity for pRb is not the only determinant of the E2F-1 activity.

Authors:  Fikret Sahin; Todd L Sladek
Journal:  Int J Biol Sci       Date:  2010-07-04       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.